Scholarlink

<p>Alzheimer’s disease (AD), the leading cause of dementia, is a multifaceted neurodegenerative disorder characterized by amyloid-beta (Aβ) aggregation, tau pathology, and neuroinflammation. Recent advances in immunotherapy have yielded monoclonal antibodies (mAbs) with unprecedented precision in targeting Aβ species, offering hope for altering the disease trajectory. Lecanemab’s selective affinity for protofibrillar Aβ disrupts early neurotoxic aggregates, providing a proactive approach for mitigating synaptic dysfunction. Donanemab, by targeting pyroglutamate-modified plaques, combines high specificity with microglial-mediated clearance, while gantenerumab enhances Fc receptor-mediated phagocytosis of both soluble and fibrillar Aβ. These therapies represent a shift from symptomatic treatment to disease modification, reducing the Aβ burden and slowing cognitive decline. However, challenges, such as amyloid-related imaging abnormalities (ARIA), underscore the complexity of balancing efficacy and safety. This review explores the transformative potential of these therapies and contextualizes their mechanisms within the evolving understanding of AD pathophysiology. This highlights the interplay between immune modulation, neuroprotection, and personalized medicine, highlighting the need for future innovations in tackling one of the most formidable challenges in neurology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月8日

查看全文
  • Taha basit Ameen,
  • Umair Ali,
  • Omme Salma,
  • Muhammad Abdul Samee,
  • Syed Muhammad Iraj Abbas,
  • Syeda Naveera Kashif,
  • Muhammad Arif Arifi,
  • Mashooque Ali,
  • Maher Khowaja,
  • Syed Muhammad Sinaan Ali,
  • Abdul Raheem

摘要

Alzheimer’s disease (AD), the leading cause of dementia, is a multifaceted neurodegenerative disorder characterized by amyloid-beta (Aβ) aggregation, tau pathology, and neuroinflammation. Recent advances in immunotherapy have yielded monoclonal antibodies (mAbs) with unprecedented precision in targeting Aβ species, offering hope for altering the disease trajectory. Lecanemab’s selective affinity for protofibrillar Aβ disrupts early neurotoxic aggregates, providing a proactive approach for mitigating synaptic dysfunction. Donanemab, by targeting pyroglutamate-modified plaques, combines high specificity with microglial-mediated clearance, while gantenerumab enhances Fc receptor-mediated phagocytosis of both soluble and fibrillar Aβ. These therapies represent a shift from symptomatic treatment to disease modification, reducing the Aβ burden and slowing cognitive decline. However, challenges, such as amyloid-related imaging abnormalities (ARIA), underscore the complexity of balancing efficacy and safety. This review explores the transformative potential of these therapies and contextualizes their mechanisms within the evolving understanding of AD pathophysiology. This highlights the interplay between immune modulation, neuroprotection, and personalized medicine, highlighting the need for future innovations in tackling one of the most formidable challenges in neurology.